REPL Stock Shot Up 80% Today – What’s The Deal With FDA?

Replimune surged 80% after reaching an agreement with the FDA to resubmit its BLA for RP1 plus nivolumab in advanced melanoma, with the agency signaling an urgent, prioritized review. The company had twice been rejected before, in July 2025 and April 2026, making the path forward a major de-risking event despite prior concerns over inconsistent FDA feedback and operational fallout. Shares also reclaimed their 200-day moving average for the first time since April 8, reinforcing the sharp shift in sentiment.

Analysis

The market is pricing in a procedural reset, not a fundamental re-underwriting of efficacy. That matters because a fast-track resubmission meaningfully compresses the binary window: the next catalyst is likely measured in weeks, not quarters, and the stock can stay momentum-driven as long as the FDA maintains an expedited posture. The 200-DMA reclaim also forces systematic buyers and short-covering to compete with event-driven capital, which can keep the tape elevated even if the underlying approval odds are still far from certain.

The second-order winner is likely not just REPL shareholders but the entire immuno-oncology platform trade. A cleaner regulatory path for one late-stage melanoma asset should improve sentiment toward smaller oncology names that have been discounted for FDA friction, especially those with combination therapy exposure or near-term submissions. The loser is the bear case built on governance collapse at the agency; if the next step is even mildly constructive, the market will reprice the probability that earlier rejections reflected process noise rather than a fatal clinical issue.

The main risk is asymmetry in expectations: after an 80% repricing, the stock is vulnerable to any delay, procedural ask, or non-committal language from the FDA. If the resubmission is accepted but the review clock stretches, the trade can de-rate quickly because the current move is front-loading approval probability into the shares. The real contrarian point is that this is now more of a timing trade than a conviction trade—good news may already be reflected unless the company can convert the resubmission into a clearly de-risked label path.

For competitors, a favorable outcome would pressure comparable small-cap oncology names with messy regulatory histories by proving the FDA is willing to rehabilitate controversial packages rather than force a full reset. That could widen the valuation spread between platform biotechs with cleaner execution and those that rely on regulatory sympathy. It also raises the odds of opportunistic capital rotation back into beaten-up biotech, but only selectively and only where the next catalyst is imminent.

Key Decisions for Investors

• Tactically long REPL for the next 2-6 weeks into the resubmission/acceptance window; use a tight stop on any sign the FDA is adding new information requests. Risk/reward is attractive only if the market is still underpricing procedural acceptance.
• Prefer REPL call spreads over outright equity if adding exposure now: the move has already reset sentiment, so defined-risk upside participation is better than chasing spot after an 80% gap.
• Use REPL strength to sell volatility against a catalyst you think is likely to be delayed rather than denied; the stock should remain headline-sensitive, but near-term IV may stay elevated enough to monetize.
• Watch for a long-biotech basket trade on confirmation of FDA acceptance: long XBI / short a discretionary small-cap biotech basket with weaker balance sheets, targeting a 1-3 month sentiment rotation.
• If REPL fails to hold above the 200-DMA on any negative procedural update, fade the move aggressively; post-gap biotech retracements can be sharp when event premium collapses.